Phase 2 Asthma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children between 1 and 5 years old who have been admitted to a children's hospital ward because of a sudden episode of asthma-like symptoms (such as bothersome coughing, wheezing, and/or difficulty breathing that affects the child's wellbeing)
- Children who are currently receiving, or have received, reliever inhaler medicine (SABA) on its own, or together with an inhaled preventer medicine (ICS), and possibly also with a leukotriene receptor antagonist medicine (LTRA), in line with Danish treatment guidelines
Who may not be able to join:
- Children admitted to hospital with pneumonia
- Children who are already taking more than 400 IU (about 10 micrograms) of vitamin D supplements per day
- Children who are taking a combination of vitamin or dietary supplements that together provide more than the recommended daily amount of vitamin D (confirm with trial site for exact amounts)
- Children who have been exclusively breastfed for the past 6 months
- Children who are malnourished — for children over 2 years old, this means a BMI below the 3rd percentile for their age; for children under 2 years old, this means a weight or height below the 3rd percentile for their age
- Children who are newly arrived refugees or immigrants from regions where rickets is a higher risk
- Children who have another ongoing lung disease
- Children diagnosed with conditions such as kidney problems, neurological or psychiatric disorders, certain heart conditions (including irregular heartbeat, a prolonged QT interval, slow heart rate, or severe heart failure), or liver problems
- Children currently taking any medicine that affects how the body absorbs or processes calcium or vitamin D
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bo Chawes, MD, DMSc, chawes@copsac.com
Phone: +4538677360
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of acute exacerbations
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.